Full Breakdown
FDA Approves Rasonque, First RAS-Targeted Pill for Metastatic Pancreatic Cancer
8/28/2026, 10:22:37 PM
Core Event: Accelerated Approval of Rasonque
On August 26, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Rasonque (daraxonrasib), a once-daily oral pill from Revolution Medicines for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are unsuitable for multi-agent chemotherapy.
Background & Context
Pancreatic adenocarcinoma accounts for most of the roughly 67,000 new U.S. pancreatic cancer cases each year and has a five-year survival rate below 13 %. Over 90 % of these tumors carry oncogenic RAS mutations, most often KRAS, which have historically been “undruggable.”
Clinical Trial Data
The FDA based its decision on the phase 3 RASolute 302 trial, a randomized, open-label study of 500 adults with previously treated metastatic disease at 59 sites in six countries. Participants received daraxonrasib 300 mg daily or the investigator’s choice of standard chemotherapy.
- Overall survival (OS): median 13.2 months vs. 6.7 months.
- Hazard ratio for death: 0.40 (95 % CI 0.30–0.53; p < 0.0001).
- Progression-free survival (PFS): median 7.2 months vs. 3.6 months.
- Objective response rate: 33.2 % vs. 11.8 %.
- Grade 3+ treatment-related adverse events: 43.6 % (daraxonrasib) vs. 57.5 % (chemotherapy).
- Discontinuation due to toxicity: 1.2 % vs. 11.2 %.
The trial did not require a companion diagnostic; patients could receive the drug regardless of documented RAS status.
Official Statements & Responses
Angelo de Claro, M.D., director of the FDA Oncology Center of Excellence, called the results “unprecedented” in an area of high unmet need. Brian M. Wolpin, M.D., MPH, principal investigator of RASolute 302, said the approval gives physicians confidence that directly inhibiting RAS can make a striking difference.
Revolution Medicines set the wholesale price of a 30-day supply at $39,800 and launched the ON Path patient-support program. Analysts noted a “Strong Buy” consensus for the company’s stock, while observers flagged the price as a potential barrier.
Verbatim Quotes
- “We have not seen this amount of benefit from any drug in pancreatic cancer so far,” — Dr. Shafia Rahman
- “Today’s approval of daraxonrasib represents an important advance for patients with metastatic pancreatic cancer, a disease that has remained extraordinarily challenging to treat.” — Dr. Pashtoon Kasi, City of Hope Orange County
What’s Next
The approval follows an earlier “safe-to-proceed” letter that allowed expanded-access treatment. Ongoing studies are testing daraxonrasib in earlier lines of therapy, in combination with chemotherapy, and in other KRAS-driven cancers such as non-small-cell lung and colorectal cancers. The European Society for Medical Oncology (ESMO) incorporated the data into its August 19, 2026 guideline update, recommending daraxonrasib monotherapy for patients with RAS G12-mutated tumors and ECOG 0–1.
Conflicting Reports & Gaps
- Severe adverse-event rates: sources cite 43.6 % and 44 % for daraxonrasib; both agree chemotherapy arm was 57.5 %.
- Price reporting: described as “nearly $40,000” in some outlets and precisely $39,800 in others; patient out-of-pocket costs are not disclosed.
- Long-term outcomes: the trial provides median survival data but lacks overall survival beyond the study period, leaving durability of benefit uncertain.
The approval of Rasonque marks a landmark shift in pancreatic cancer therapy, offering the first RAS-targeted option for a disease that has long resisted molecular intervention.
